Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12.

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. Abstract Text:

Interleukin-12 (IL-12) is a cytokine with effects on immune function and hematopoiesis. In this article, the authors describe two patients with renal cell cancer in whom grade 4 neutropenia and grade 3 hemolytic anemia developed, respectively, during treatment with twice-weekly intravenous recombinant human interleukin-12 (rhIL-12) during a phase 1 trial. The severe neutropenia was associated with bone marrow agranulocytosis and a preponderance of large granular lymphocytes in the peripheral blood, whereas the hemolytic anemia was negative for the Coombs test and associated with splenomegaly. The agranulocytosis and hemolytic anemia persisted after the rhIL-12 was stopped, but both subsequently responded to treatment with cyclophosphamide. steroids, or both. These findings indicate that rhIL-12 can induce unique hematologic toxic effects that can be reversed with immunosuppressive drugs.

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. Publishing Authors By Initials

For similar proteins: recombinant proteins research abstracts see: proteins: recombinant proteins research

PUBMED ID PMID:

MEDLINE DATE: 2001 Jan-Feb

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

VOLUME: 24

Page Numbers: 91-8

Journal Abbreviation: J. Immunother.

ISSN: 1524-9557

DAY: 18

MONTH: 03

YEAR: 2008

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9706083

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. Keywords Mesh Terms:

KEYWORDS: Recombinant Proteins

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. Information

Substance Name: Interleukin-12

Registry Number: 187348-17-0

Grant and Affiliation Information for Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12.

AFFILIATION: Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Immunother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12 Related Publications

• A comparison of manual and automatic methods for registering scans of the head.
• A quantitative index of substrate promiscuity.
• A quarter of a century of adult peritoneal dialysis-related peritonitis at an Australian medical center.
• A theoretical validation of the substrate depletion approach to determining kinetic parameters.
• Analysis of face powder.
• Arsenic risk mapping in Bangladesh: a simulation technique of cokriging estimation from regional count data.
• Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs.
• Effect of melanoma on immune function in the regional lymph node basin.
• Fine needle aspiration cytology of clear cell "sugar" tumor (PEComa) of the lung: Report of a case.
• Food allergy: diagnosis and management.
• Functional promiscuity correlates with conformational heterogeneity in A-class glutathione S-transferases.
• HPLC-detected albuminuria predicts mortality.
• Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes.
• Linking mental health and after school systems for children in urban poverty: preventing problems, promoting possibilities.
• Management of long-bone non-unions.
• Nile Red Is a Fluorescent Allosteric Substrate of Cytochrome P450 3A4.
• Optimization of bivalent glutathione S-transferase inhibitors by combinatorial linker design.
• Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.
• Photoinduced optical absorption and 400-nm luminescence in low-germanium-content optical f iber preforms irradiated with ArF and KrF excimer-laser light.
• Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
• Potential of alphavirus vectors in the treatment of advanced solid tumors.
• Premature rupture of the membranes.
• Principles of management of septic non-union of fracture.
• Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site.
• Reassessing the definition of heartworm infection in cats.
• Semliki Forest virus vectors expressing the H and HN genes of measles and mumps viruses reduce immunity induced by the envelope protein genes of rubella virus.
• Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic?
• The Sanitary Privy and Its Relation to Public Health.
• The effect of endocrines on fibro adenosis.
• The present-day treatment of osteomyelitis.